GoodRx Receives Analyst 'Moderate Buy' Rating

Summary

GoodRx Holdings, Inc. (NASDAQ: GDRX) has been given an average ‘moderate buy’ rating by eleven analysts. Five analysts recommend holding the stock, five recommend buying, and one gives a strong buy rating. The average 12-month price target is $6.55, with recent targets including Goldman Sachs at $5.00, Truist at $5.50, Wells Fargo at $7.00, and UBS at $5.25. GoodRx reported last quarter’s earnings per share of $0.09, surpassing expectations, with revenue of $202.97 million, an increase of 2.6% year-over-year.Market Beat

Impact Analysis

The event is classified at the company level as it specifically pertains to GoodRx Holdings, Inc. The company’s stock is positioned at a ‘moderate buy’ rating, indicating a relatively positive outlook. The diverse price targets from analysts, ranging from $5.00 to $7.00, suggest varied expectations regarding the company’s future performance. The reported earnings per share of $0.09, beating expectations, along with a revenue increase of 2.6%, signal a positive financial trajectory for GoodRx, which might encourage investor confidence.Market Beat This event provides investment opportunities, particularly for those already considering or holding GoodRx stocks. Investors might explore buying at current levels, given the positive earnings report and analyst ratings, but they should also assess the range of price targets and remain aware of market conditions and company-specific developments.